Genscript Biotech Corp (1548)

Currency in HKD
34.44
+1.08(+3.24%)
Closed·
1548 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
32.5034.76
52 wk Range
10.3635.22
Key Statistics
Bid/Ask
34.42 / 34.44
Prev. Close
33.36
Open
33.2
Day's Range
32.5-34.76
52 wk Range
10.36-35.22
Volume
34.78M
Average Volume (3m)
33.22M
1-Year Change
85.9611%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1548 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.16
Downside
-15.34%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Genscript Biotech Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.16
(-15.34% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy35.00+1.63%23.00Maintain19/08/2026
JPMorgan
Buy23.00-33.22%20.00Maintain04/08/2026
JPMorgan
Buy20.00-41.93%24.00Maintain19/03/2026

Genscript Biotech Corp Earnings Call Summary for H1/2026

  • GenScript H1 2026 revenue rose 27.3% YoY to HKD 404.2M; adjusted net profit surged 203.3% to HKD 62.5M on strong AIDD demand and operating leverage.
  • Life Science Group revenue grew 28.8% to HKD 319M, beating guidance by 10ppts; adjusted operating profit doubled to HKD 94M on higher-margin validation services.
  • Management raised FY2026 guidance: Life Science Group revenue growth to 25-30% with 25%+ operating margin; ProBio growth also 25-30% with 2027 EBITDA positive.
  • AIDD orders expected to double in H2 2026; company targeting validation services with 20ppt higher margins than traditional protein work, four-day turnaround.
  • Shares fell 4.23% to $24.88 despite strong results; company plans US$130M capex in 2026, funded by US$830M cash without equity financing needed.
Last Updated: 17/08/2026, 10:36 am
Read Full Transcript

Earnings

Latest Release
11/09/2025
EPS / Forecast
-0.02 / 0.62
Revenue / Forecast
518.77M / --
EPS Revisions
Last 90 days

1548 Income Statement

Compare 1548 to Peers and Sector

Metrics to compare
1548
Peers
Sector
Relationship
P/E Ratio
−15.1x−4.0x−0.4x
PEG Ratio
0.120.210.00
Price/Book
2.5x4.1x2.6x
Price / LTM Sales
11.4x5.3x3.1x
Upside (Analyst Target)
−7.2%8.2%48.9%
Fair Value Upside
Unlock4.4%6.2%Unlock

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
436.69M19.97%15.04B
Other Institutional Investors
815.05M37.27%28.07B
Public Companies & Retail Investors
935.12M42.76%32.21B
Total
2.19B100.00%75.32B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
GenScript Corporation36.58%799,999,12327,551,970
Vanguard Capital Management, LLC2.35%51,343,0991,768,256

People Also Watch

17.83
1530
+8.06%
4.430
1357
+1.26%
18.75
0175
+1.13%
115.20
9618
+0.61%
93.15
1211
+1.47%

FAQ

What Is the Genscript Biotech Corp (1548) Stock Price Today?

The Genscript Biotech Corp stock price today is 34.44 HKD.

What Stock Exchange Does Genscript Biotech Corp Trade On?

Genscript Biotech Corp is listed and trades on the Hong Kong Stock Exchange.

What Is the Stock Symbol for Genscript Biotech Corp?

The stock symbol for Genscript Biotech Corp is "1548."

What Is the Genscript Biotech Corp Market Cap?

As of today, Genscript Biotech Corp market cap is 75.32B HKD.

What Is Genscript Biotech Corp's Earnings Per Share (TTM)?

The Genscript Biotech Corp EPS (TTM) is -0.29.

From a Technical Analysis Perspective, Is 1548 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Genscript Biotech Corp Stock Split?

Genscript Biotech Corp has split 0 times.

How Many Employees Does Genscript Biotech Corp Have?

Genscript Biotech Corp has 6135 employees.

What is the current trading status of Genscript Biotech Corp (1548)?

As of 23/08/2026, Genscript Biotech Corp (1548) is trading at a price of 34.44 HKD, with a previous close of 33.36 HKD. The stock has fluctuated within a day range of 32.50 HKD to 34.76 HKD, while its 52-week range spans from 10.36 HKD to 35.22 HKD.

What Is Genscript Biotech Corp (1548) Price Target According to Analysts?

The average 12-month price target for Genscript Biotech Corp is 29.16 HKD, with a high estimate of 36.05015674 HKD and a low estimate of 15.90125392 HKD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -15.34% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.